Summit Securities Group’s AbbVie ABBV Stock Holding History

Summit Securities Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-25,000	Closed	-$3.87M	–	412
2023 Q4	$3.87M	Hold	25,000	–	–	0.35%	53
2023 Q3	$3.73M	Hold	25,000	–	–	0.38%	43
2023 Q2	$3.37M	Buy	25,000 +5,000	+25%	+$733K	0.44%	40
2023 Q1	$3.19M	Buy	+20,000	New	+$3.06M	0.26%	52
2022 Q4	–	Sell	-6,000	Closed	-$805K	–	1125
2022 Q3	$805K	Buy	6,000 +3,000	+100%	+$430K	0.06%	189
2022 Q2	$459K	Sell	3,000 -7,000	-70%	-$1.07M	0.06%	194
2022 Q1	$1.62M	Sell	10,000 -70,000	-88%	-$10.2M	0.18%	102
2021 Q4	$10.8M	Buy	80,000 +79,500	+15,900%	+$9.39M	0.51%	36
2021 Q3	$5.39M	Sell	500 -264	-35%	-$30.2K	0.42%	54
2021 Q2	$8.61M	Buy	764 +334	+78%	+$37.6K	0.71%	28
2021 Q1	$4.65M	Sell	430 -470	-52%	-$50.3K	0.51%	35
2020 Q4	$9.64M	Buy	900 +400	+80%	+$38.4K	0.81%	17
2020 Q3	$4.38M	Sell	500 -25	-5%	-$2.35K	0.46%	43
2020 Q2	$5.15M	Buy	525 +215	+69%	+$18.9K	0.64%	26
2020 Q1	$2.36M	Sell	310 -1,990	-87%	-$170K	0.42%	54
2019 Q4	$20.4M	Buy	+2,300	New	+$191K	1.54%	11
2019 Q1	–	Sell	-32	Closed	-$295K	–	191
2018 Q4	$295K	Buy	+32	New	+$2.81K	0.03%	245

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Summit Securities Group's ABBV Position: Q2 2026 in Review

Summit Securities Group reduced its AbbVie (ABBV) stake by 73% in Q2 2026, selling an estimated $706K and leaving 1,210 shares worth $304K. The position accounts for 0.03% of the portfolio, ranked #224.

Summit Securities Group first reported a position in ABBV in Q2 2013 and has held it in 49 quarters since. The position peaked at $14.1M in Q4 2021. 4,216 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Summit Securities Group held 1,210 shares of AbbVie worth $304K as of Q2 2026.
Summit Securities Group sold 3,280 AbbVie shares in Q2 2026, an estimated $706K.
AbbVie made up 0.03% of Summit Securities Group's portfolio in Q2 2026, its #224 holding.
Summit Securities Group first reported a position in AbbVie in Q2 2013 and has held it in 49 quarters since.
Summit Securities Group's AbbVie position peaked at $14.1M in Q4 2021.
4,216 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.